ALLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Allogene Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -47.88%.
The historical data trend for Allogene Therapeutics's ROCE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
ROCE % | Get a 7-Day Free Trial | -28.27 | -28.41 | -16.87 | -37.90 | -45.79 |
Allogene Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
ROCE % | Get a 7-Day Free Trial | -54.48 | -45.89 | -36.22 | -44.94 | -47.88 |
Allogene Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:
ROCE % | = | EBIT | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(A: Dec. 2023 ) | (A: Dec. 2022 ) | (A: Dec. 2023 ) | |||||
= | -314.492 | / | ( ( (821.579 - 53.728) | + | (642.837 - 37.079) ) | / 2 ) | |
= | -314.492 | / | ( (767.851 | + | 605.758) | / 2 ) | |
= | -314.492 | / | 686.8045 | ||||
= | -45.79 % |
Allogene Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:
ROCE % | = | EBIT (1) | / | ( (Capital Employed | + | Capital Employed) | / count ) |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | EBIT | / | ( ( (Total Assets - Total Current Liabilities) | + | (Total Assets - Total Current Liabilities) ) | / count ) | |
(Q: Mar. 2024 ) | (Q: Dec. 2023 ) | (Q: Mar. 2024 ) | |||||
= | -278.016 | / | ( ( (642.837 - 37.079) | + | (586.35 - 30.894) ) | / 2 ) | |
= | -278.016 | / | ( ( 605.758 | + | 555.456 ) | / 2 ) | |
= | -278.016 | / | 580.607 | ||||
= | -47.88 % |
(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (NAS:ALLO) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Thank you for viewing the detailed overview of Allogene Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Deborah M. Messemer | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Geoffrey M. Parker | officer: CHIEF FINANCIAL OFFICER | 15 RIORDAN PLACE, MENLO PARK CA 94025 |
Earl Martin Douglas | officer: GENERAL COUNSEL | BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067 |
Yinlin Jack Chen | officer: SVP, Finance | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Stephen Mayo | director | 2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
Timothy L. Moore | officer: Chief Technical Officer | C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404 |
Lillian Smith | officer: VP, Corporate Counsel | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Veer Bhavnagri | officer: General Counsel | C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Zachary Roberts | officer: EVP of R&D | C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219 |
Owen N. Witte | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Rafael Amado | officer: EVP of R&D and CMO | 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080 |
Alison Moore | officer: Chief Technical Officer | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Eric Thomas Schmidt | officer: Chief Financial Officer | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
David D Chang | director, officer: President and CEO | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Jon Winkelried | 10 percent owner | C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004 |
From GuruFocus
By sperokesalga sperokesalga • 04-20-2023
By sperokesalga sperokesalga • 04-17-2023
By Marketwired • 11-02-2023
By Marketwired • 11-03-2023
By GlobeNewswire GlobeNewswire • 05-11-2023
By Marketwired • 10-16-2023
By Marketwired • 10-30-2023
By sperokesalga sperokesalga • 03-02-2023
By sperokesalga sperokesalga • 05-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.